Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Resectable NSCLC × sintilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 34 Carcinoma, Hepatocellular 31 Carcinoma, Non-Small-Cell Lung 22 Colorectal Neoplasms 16 Esophageal Squamous Cell Carcinoma 12 Lung Neoplasms 9 Rectal Neoplasms 7 Nasopharyngeal Carcinoma 7 Esophageal Neoplasms 6 Cholangiocarcinoma 6 Squamous Cell Carcinoma of Head and Neck 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Small Cell Lung Carcinoma 4 Pancreatic Neoplasms 4 Neoplasms 4 Neoplasm Metastasis 4 Colonic Neoplasms 4 Carcinoma, Renal Cell 4 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Extranodal NK-T-Cell 3 Carcinoma 3 Breast Neoplasms 3 Spinocerebellar Degenerations 2 Sarcoma 2 Nonsquamous Non-Small Cell Lung Cancer 2 Neuroendocrine Tumors 2 Lymphoma, T-Cell, Peripheral 2 Locally Advanced Rectal Cancer 2 Glioblastoma 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡